GB8928874D0
(en)
*
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
GB9021679D0
(en)
*
|
1990-10-05 |
1990-11-21 |
Gorman Scott David |
Antibody preparation
|
US6197298B1
(en)
|
1991-04-19 |
2001-03-06 |
Tanox, Inc. |
Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
|
US6129916A
(en)
*
|
1991-04-19 |
2000-10-10 |
Tanox, Inc. |
Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
|
US5872222A
(en)
*
|
1991-04-19 |
1999-02-16 |
Tanox Biosystems, Inc. |
Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
|
CA2065658A1
(en)
*
|
1991-04-19 |
1992-10-20 |
Tse-Wen Chang |
Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
|
US6106835A
(en)
*
|
1991-04-19 |
2000-08-22 |
Tanox, Inc. |
Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
|
US5817308A
(en)
*
|
1994-02-14 |
1998-10-06 |
University Of Rochester |
Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
EP0977862B8
(de)
|
1997-04-30 |
2009-09-16 |
Twinstrand Therapeutics Inc. |
Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
|
US6103466A
(en)
*
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
AU756620B2
(en)
|
1997-07-14 |
2003-01-16 |
University Of Liege |
Mutations in the myostation gene cause double-muscling in mammals
|
GB9815909D0
(en)
*
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
US6531125B1
(en)
|
1999-03-02 |
2003-03-11 |
Twinstrand Therapeutics Inc. |
Antiviral ricin-like proteins
|
CA2305716A1
(en)
|
1999-05-28 |
2000-11-28 |
University Of Guelph |
Method for assay of wbpm
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2003221575B2
(en)
|
2002-05-02 |
2010-06-10 |
Dalia Barsyte |
Teneurin C-terminal associated peptides (TCAP) and uses thereof
|
JP5576010B2
(ja)
|
2003-08-04 |
2014-08-20 |
ザ・ホスピタル・フォー・シック・チルドレン |
ラフォラ病遺伝子
|
US7427670B2
(en)
|
2003-12-19 |
2008-09-23 |
Cytochroma Inc. |
Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
|
TWI364458B
(en)
|
2004-08-27 |
2012-05-21 |
Wyeth Res Ireland Ltd |
Production of tnfr-lg
|
US7335491B2
(en)
|
2004-08-27 |
2008-02-26 |
Wyeth Research Ireland Limited |
Production of anti-abeta
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
ATE530198T1
(de)
|
2005-02-16 |
2011-11-15 |
Univ Zuerich |
Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
CN101541950A
(zh)
|
2006-07-13 |
2009-09-23 |
惠氏公司 |
糖蛋白的产生
|
US8450464B2
(en)
*
|
2006-10-02 |
2013-05-28 |
Medarex, Inc. |
Human monoclonal antibodies that bind CXCR4
|
KR20090069330A
(ko)
|
2006-10-12 |
2009-06-30 |
와이어쓰 |
유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
|
MX2009004519A
(es)
|
2006-11-03 |
2009-05-12 |
Wyeth Corp |
Sustancias que inhiben la glucolisis en un cultivo de celulas.
|
US20100247552A1
(en)
|
2006-11-10 |
2010-09-30 |
Massachusetts Institute Of Technology |
Pak modulators
|
DE102006062398A1
(de)
|
2006-12-20 |
2008-06-26 |
Edi (Experimentelle & Diagnostische Immunologie) Gmbh |
Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
|
DK2115126T3
(en)
|
2007-03-02 |
2015-05-04 |
Wyeth Llc |
Use of copper and glutamate in cell culture for the preparation of polypeptides
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
WO2010056550A1
(en)
|
2008-10-29 |
2010-05-20 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
CN102271707B
(zh)
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
US9085795B2
(en)
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
ES2725356T3
(es)
|
2009-04-29 |
2019-09-23 |
Henry M Jackson Found Advancement Military Medicine Inc |
Anticuerpos monoclonales de ERG2 y su uso terapéutico
|
WO2011003996A1
(en)
|
2009-07-09 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
In vivo tumor vasculature imaging
|
AU2011223456A1
(en)
|
2010-03-03 |
2012-10-18 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
WO2012023085A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
EP3974453A3
(de)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
|
JP6130350B2
(ja)
|
2011-03-30 |
2017-05-17 |
アブリンクス エン.ヴェー. |
TNFαに対する単一ドメイン抗体で免疫障害を処置する方法
|
KR20170021919A
(ko)
|
2011-10-21 |
2017-02-28 |
화이자 인코포레이티드 |
철을 첨가하여 세포 배양을 개선하는 방법
|
EP2897631A4
(de)
|
2012-08-31 |
2016-10-05 |
Univ Virginia Patent Found |
Zielpeptide für immuntherapie und diagnostik
|
EP4088737A3
(de)
|
2012-09-05 |
2023-02-08 |
University Of Virginia Patent Foundation |
Target-peptide für therapie und diagnostik von kolorektalkarzinomen
|
EP2903692B1
(de)
|
2012-10-08 |
2019-12-25 |
St. Jude Children's Research Hospital |
Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
|
CA2894885A1
(en)
|
2012-12-13 |
2014-06-19 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
WO2015013671A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
WO2015140708A1
(en)
|
2014-03-19 |
2015-09-24 |
Pfizer Inc. |
Method of cell culture
|
CA2945816A1
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
BR112017001579A2
(pt)
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
WO2017051347A2
(en)
|
2015-09-23 |
2017-03-30 |
Pfizer Inc. |
Cells and method of cell culture
|
GB201520191D0
(en)
|
2015-11-16 |
2015-12-30 |
Cancer Rec Tech Ltd |
T-cell receptor and uses thereof
|
IL261999B2
(en)
|
2016-04-05 |
2023-04-01 |
Pfizer |
Cell culture process
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
CA3056182A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
CN111868223A
(zh)
|
2017-09-15 |
2020-10-30 |
百时美施贵宝公司 |
大规模生产目的多肽过程中的在线生物质电容监测
|
WO2019145475A2
(en)
|
2018-01-25 |
2019-08-01 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
KR20200133240A
(ko)
|
2018-03-16 |
2020-11-26 |
브리스톨-마이어스 스큅 컴퍼니 |
단백질 생산 동안의 대사 효소 활성 및 디술피드 결합 환원
|
US20210048437A1
(en)
|
2018-03-26 |
2021-02-18 |
Glycanostiion , s.r.o. |
Means and methods for glycoprofiling of a protein
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
US20220073942A1
(en)
|
2018-12-06 |
2022-03-10 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
US20220332799A1
(en)
|
2019-09-04 |
2022-10-20 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
CA3214934A1
(en)
|
2021-04-12 |
2022-10-20 |
Madhavan Nallani |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
CN115073602B
(zh)
*
|
2022-05-30 |
2023-10-03 |
苏州百道医疗科技有限公司 |
一种抗cd3重组兔单克隆抗体及其应用
|